Karen Louise Mossman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3221624/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation. Lab on A Chip, 2022, 22, 1171-1186.	6.0	27
2	A Universal DNA Aptamer that Recognizes Spike Proteins of Diverse SARSâ€CoVâ€2 Variants of Concern. Chemistry - A European Journal, 2022, 28, .	3.3	30
3	Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Science Advances, 2022, 8, eabj9815.	10.3	29
4	A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner. International Journal of Molecular Sciences, 2022, 23, 1754.	4.1	9
5	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 2022, 185, 896-915.e19.	28.9	189
6	A Universal DNA Aptamer that Recognizes Spike Proteins of Diverse SARS oVâ€2 Variants of Concern. Chemistry - A European Journal, 2022, 28, e202200524.	3.3	9
7	BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Reports, 2022, 38, 110502.	6.4	51
8	IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor TÂcell activity. Molecular Therapy - Oncolytics, 2022, 25, 16-30.	4.4	4
9	The Thiazole-5-Carboxamide GPS491 Inhibits HIV-1, Adenovirus, and Coronavirus Replication by Altering RNA Processing/Accumulation. Viruses, 2022, 14, 60.	3.3	10
10	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. Npj Vaccines, 2022, 7, 49.	6.0	7
11	Discovery and Use of Long dsRNA Mediated RNA Interference to Stimulate Antiviral Protection in Interferon Competent Mammalian Cells. Frontiers in Immunology, 2022, 13, .	4.8	5
12	Intronic regulation of SARS-CoV-2 receptor (ACE2) expression mediated by immune signaling and oxidative stress pathways. IScience, 2022, 25, 104614.	4.1	6
13	Unraveling the Zoonotic Origin and Transmission of SARS-CoV-2. Trends in Ecology and Evolution, 2021, 36, 180-184.	8.7	59
14	Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. Cancers, 2021, 13, 806.	3.7	67
15	Zooanthroponotic potential of SARS-CoV-2 and implications of reintroduction into human populations. Cell Host and Microbe, 2021, 29, 160-164.	11.0	41
16	Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. IScience, 2021, 24, 102477.	4.1	49
17	Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 4843.	4.1	8
18	Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells. International Journal of Molecular Sciences, 2021, 22, 4893.	4.1	12

#	Article	IF	CITATIONS
19	Detecting single cell interferon-beta production using a fluorescent reporter telomerase-immortalized human fibroblast cell line. STAR Protocols, 2021, 2, 100436.	1.2	0
20	Diverse high-affinity DNA aptamers for wild-type and B.1.1.7 SARS-CoV-2 spike proteins from a pre-structured DNA library. Nucleic Acids Research, 2021, 49, 7267-7279.	14.5	77
21	Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. Communications Biology, 2021, 4, 859.	4.4	13
22	Highâ€Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wildâ€Type and B.1.1.7 SARSâ€CoVâ€2 in Unprocessed Saliva. Angewandte Chemie, 2021, 133, 24468-24476.	2.0	21
23	AHR signaling is induced by infection with coronaviruses. Nature Communications, 2021, 12, 5148.	12.8	38
24	Evolutionary trajectory of SARS-CoV-2 and emerging variants. Virology Journal, 2021, 18, 166.	3.4	105
25	Highâ€Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wildâ€Type and B.1.1.7 SARSâ€CoVâ€2 in Unprocessed Saliva. Angewandte Chemie - International Edition, 2021, 60, 24266-24274.	13.8	101
26	Molecular Determinants of SARS-CoV-2 Variants. Trends in Microbiology, 2021, 29, 871-873.	7.7	31
27	Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. Cell Reports, 2021, 37, 109892.	6.4	60
28	Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer. Cancers, 2021, 13, 5590.	3.7	0
29	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. Cell and Bioscience, 2021, 11, 202.	4.8	13
30	Genetic modification of oncolytic viruses to enhance antitumor immunity. Methods in Enzymology, 2020, 635, 231-250.	1.0	2
31	Novel Insights Into Immune Systems of Bats. Frontiers in Immunology, 2020, 11, 26.	4.8	212
32	Bat Influenza Viruses: Making a Double Agent of MHC Class II. Trends in Microbiology, 2020, 28, 703-706.	7.7	5
33	Gene expression and <i>in situ</i> protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. European Respiratory Journal, 2020, 56, 2001123.	6.7	138
34	Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infectious Diseases, 2020, 26, 2054-2063.	4.3	118
35	A Comparison of Whole Genome Sequencing of SARS-CoV-2 Using Amplicon-Based Sequencing, Random Hexamers, and Bait Capture. Viruses, 2020, 12, 895.	3.3	86
36	Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection. IScience, 2020, 23, 101864.	4.1	6

#	Article	IF	CITATIONS
37	De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology, 2020, 3, 645.	4.4	30
38	Positive Selection of a Serine Residue in Bat IRF3 Confers Enhanced Antiviral Protection. IScience, 2020, 23, 100958.	4.1	34
39	Seroprevalence in Bats and Detection of Borrelia burgdorferi in Bat Ectoparasites. Microorganisms, 2020, 8, 440.	3.6	6
40	Hypoxia-Driven Immune Escape in the Tumor Microenvironment. Cells, 2020, 9, 992.	4.1	156
41	Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus. Journal of General Virology, 2020, 101, 1251-1260.	2.9	12
42	Molecular Pathogenesis of Middle East Respiratory Syndrome (MERS) Coronavirus. Current Clinical Microbiology Reports, 2019, 6, 139-147.	3.4	18
43	Oncolytic viruses: how "lytic―must they be for therapeutic efficacy?. Oncolmmunology, 2019, 8, e1581528.	4.6	99
44	Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. Scientific Reports, 2019, 9, 1865.	3.3	21
45	Bats and Coronaviruses. Viruses, 2019, 11, 41.	3.3	357
46	Direct binding and internalization of diverse extracellular nucleic acid species through the collagenous domain of class A scavenger receptors. Immunology and Cell Biology, 2018, 96, 922-934.	2.3	6
47	Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. Journal of Immunology, 2018, 200, 450-458.	0.8	78
48	Commentary: Phyllostomid bat microbiome composition is associated to host phylogeny and feeding strategies. Frontiers in Microbiology, 2018, 9, 2863.	3.5	2
49	Active-site mTOR inhibitors augment HSV1-dICPO infection in cancer cells via dysregulated eIF4E/4E-BP axis. PLoS Pathogens, 2018, 14, e1007264.	4.7	20
50	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. Oncolmmunology, 2018, 7, e1503032.	4.6	67
51	Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. Journal of Experimental Medicine, 2017, 214, 1153-1167.	8.5	80
52	Interferon-Dependent Induction of Clr-b during Mouse Cytomegalovirus Infection Protects Bystander Cells from Natural Killer Cells via NKR-P1B-Mediated Inhibition. Journal of Innate Immunity, 2017, 9, 343-358.	3.8	9
53	USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation. Nature Immunology, 2017, 18, 54-63.	14.5	90
54	Type I Interferon Induced by Streptococcus suis Serotype 2 is Strain-Dependent and May Be Beneficial for Host Survival. Frontiers in Immunology, 2017, 8, 1039.	4.8	17

#	Article	IF	CITATIONS
55	The Importance of Physiologically Relevant Cell Lines for Studying Virus–Host Interactions. Viruses, 2016, 8, 297.	3.3	23
56	Viral Evasion Strategies in Type I IFN Signaling – A Summary of Recent Developments. Frontiers in Immunology, 2016, 7, 498.	4.8	113
57	S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3. Nature Immunology, 2016, 17, 514-522.	14.5	67
58	Membrane Perturbation-Associated Ca ²⁺ Signaling and Incoming Genome Sensing Are Required for the Host Response to Low-Level Enveloped Virus Particle Entry. Journal of Virology, 2016, 90, 3018-3027.	3.4	26
59	Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nature Immunology, 2016, 17, 65-75.	14.5	305
60	Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma. Molecular Therapy - Oncolytics, 2015, 2, 15004.	4.4	9
61	Widely Used Herpes Simplex Virus 1 ICPO Deletion Mutant Strain dl1403 and Its Derivative Viruses Do Not Express Glycoprotein C Due to a Secondary Mutation in the gC Gene. PLoS ONE, 2015, 10, e0131129.	2.5	11
62	Methods related to molecular virology. Methods, 2015, 90, 1-2.	3.8	0
63	HSV Cheats the Executioner. Cell Host and Microbe, 2015, 17, 148-151.	11.0	5
64	The Role of Palmitoylation for Protein Recruitment to the Inner Membrane Complex of the Malaria Parasite. Journal of Biological Chemistry, 2015, 290, 1712-1728.	3.4	66
65	The role of oncolytic virus immunotherapies to subvert cancer immune evasion. Future Oncology, 2015, 11, 675-689.	2.4	18
66	Cellular Protein WDR11 Interacts with Specific Herpes Simplex Virus Proteins at the <i>trans</i> -Golgi Network To Promote Virus Replication. Journal of Virology, 2015, 89, 9841-9852.	3.4	10
67	Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic. Current Opinion in Virology, 2015, 13, 11-16.	5.4	19
68	A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology. Journal of Immunology, 2015, 195, 4650-4659.	0.8	5
69	Class A Scavenger Receptor–Mediated Double-Stranded RNA Internalization Is Independent of Innate Antiviral Signaling and Does Not Require Phosphatidylinositol 3-Kinase Activity. Journal of Immunology, 2015, 195, 3858-3865.	0.8	36
70	Consensus guidelines for the detection of immunogenic cell death. Oncolmmunology, 2014, 3, e955691.	4.6	686
71	Identifying roadblocks to successful oncolytic virotherapy: what are they and how do we approach them?. Future Virology, 2014, 9, 695-697.	1.8	0
72	Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. Molecular Therapy, 2014, 22, 123-131.	8.2	93

#	Article	IF	CITATIONS
73	Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies. Molecular Therapy, 2014, 22, 251-256.	8.2	160
74	Novel Roles of Cytoplasmic ICPO: Proteasome-Independent Functions of the RING Finger Are Required To Block Interferon-Stimulated Gene Production but Not To Promote Viral Replication. Journal of Virology, 2014, 88, 8091-8101.	3.4	20
75	Type-I interferon signaling through ISCF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3206-13.	7.1	149
76	Extracellular dsRNA: Its Function and Mechanism of Cellular Uptake. Journal of Interferon and Cytokine Research, 2014, 34, 419-426.	1.2	31
77	Danger, diversity and priming in innate antiviral immunity. Cytokine and Growth Factor Reviews, 2014, 25, 525-531.	7.2	44
78	Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by KRAS Activity. Journal of Virology, 2014, 88, 6885-6895.	3.4	21
79	Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses. Journal of Visualized Experiments, 2014, , e52232.	0.3	3
80	HIV-1 gp120 Induces TLR2- and TLR4-Mediated Innate Immune Activation in Human Female Genital Epithelium. Journal of Immunology, 2013, 191, 4246-4258.	0.8	124
81	MARCO Is Required for TLR2- and Nod2-Mediated Responses to <i>Streptococcus pneumoniae</i> and Clearance of Pneumococcal Colonization in the Murine Nasopharynx. Journal of Immunology, 2013, 190, 250-258.	0.8	103
82	Recent advances in understanding viral evasion of type I interferon. Immunology, 2013, 138, 190-197.	4.4	136
83	Novel paradigms of innate immune sensing of viral infections. Cytokine, 2013, 63, 219-224.	3.2	18
84	Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncolmmunology, 2013, 2, e27138.	4.6	22
85	Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. Cancer Immunology Research, 2013, 1, 309-319.	3.4	62
86	Proinflammatory Cytokines and Chemokines - But not Interferon-β - Produced in Response to HSV-2 in Primary Human Genital Epithelial Cells are Associated with Viral Replication and the Presence of the Virion Host Shutoff Protein. American Journal of Reproductive Immunology, 2013, 70, 199-212.	1.2	11
87	The Herpes Simplex Virus 1-Encoded Envelope Glycoprotein B Activates NF-ήB through the Toll-Like Receptor 2 and MyD88/TRAF6-Dependent Signaling Pathway. PLoS ONE, 2013, 8, e54586.	2.5	92
88	Herpes Simplex Virus 1 Tegument Protein US11 Downmodulates the RLR Signaling Pathway via Direct Interaction with RIG-I and MDA-5. Journal of Virology, 2012, 86, 3528-3540.	3.4	148
89	Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmunity Reviews, 2012, 11, 863-872.	5.8	155
90	The Nitric Oxide Pathway Provides Innate Antiviral Protection in Conjunction with the Type I Interferon Pathway in Fibroblasts. PLoS ONE, 2012, 7, e31688.	2.5	45

#	Article	IF	CITATIONS
91	Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy. Molecular Therapy, 2011, 19, 335-344.	8.2	88
92	Methods related to molecular virology. Methods, 2011, 55, 107-108.	3.8	0
93	A critical role for ILâ€15 in TLRâ€mediated innate antiviral immunity against genital HSVâ€2 infection. Immunology and Cell Biology, 2011, 89, 663-669.	2.3	13
94	Retroviral expression of MIR2 decreases both surface MHC class I and the alloimmune CTL response. Journal of Tissue Engineering and Regenerative Medicine, 2011, 5, 520-528.	2.7	3
95	Varicella-Zoster Virus Immediate-Early Protein ORF61 Abrogates the IRF3-Mediated Innate Immune Response through Degradation of Activated IRF3. Journal of Virology, 2011, 85, 11079-11089.	3.4	110
96	Membrane Perturbation Elicits an IRF3-Dependent, Interferon-Independent Antiviral Response. Journal of Virology, 2011, 85, 10926-10931.	3.4	39
97	IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research, 2011, 71, 2497-2506.	0.9	49
98	Cellular Localization of the Herpes Simplex Virus ICPO Protein Dictates Its Ability to Block IRF3-Mediated Innate Immune Responses. PLoS ONE, 2010, 5, e10428.	2.5	84
99	Recognition of Virus Infection and Innate Host Responses to Viral Gene Therapy Vectors. Molecular Therapy, 2010, 18, 1422-1429.	8.2	53
100	An Accessory to the †Trinity': SR-As Are Essential Pathogen Sensors of Extracellular dsRNA, Mediating Entry and Leading to Subsequent Type I IFN Responses. PLoS Pathogens, 2010, 6, e1000829.	4.7	122
101	dsRNA and the innate antiviral immune response. Future Virology, 2010, 5, 325-341.	1.8	29
102	Replication of Subgenomic Hepatitis C Virus Replicons in Mouse Fibroblasts Is Facilitated by Deletion of Interferon Regulatory Factor 3 and Expression of Liver-Specific MicroRNA 122. Journal of Virology, 2010, 84, 9170-9180.	3.4	63
103	Treating Viral Exacerbations of Chronic Obstructive Pulmonary Disease: Insights from a Mouse Model of Cigarette Smoke and H1N1 Influenza Infection. PLoS ONE, 2010, 5, e13251.	2.5	90
104	Mechanisms Employed by Herpes Simplex Virus 1 to Inhibit the Interferon Response. Journal of Interferon and Cytokine Research, 2009, 29, 599-608.	1.2	86
105	Long Double-Stranded RNA Induces an Antiviral Response Independent of IFN Regulatory Factor 3, IFN-β Promoter Stimulator 1, and IFN. Journal of Immunology, 2009, 183, 6545-6553.	0.8	60
106	Cell Fusion-Induced Activation of Interferon-Stimulated Genes Is Not Required for Restriction of a Herpes Simplex Virus VP16/ICP0 Mutant in Heterokarya Formed between Permissive and Restrictive Cells. Journal of Virology, 2009, 83, 8976-8979.	3.4	3
107	Innate and Adaptive Immune Responses to Herpes Simplex Virus. Viruses, 2009, 1, 979-1002.	3.3	102
108	Differential Modification of Interferon Regulatory Factor 3 following Virus Particle Entry. Journal of Virology, 2009, 83, 4013-4022.	3.4	32

#	Article	IF	CITATIONS
109	Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-β production. Molecular Immunology, 2009, 46, 821-829.	2.2	26
110	Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production. Molecular Immunology, 2009, 46, 393-399.	2.2	46
111	Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Molecular Immunology, 2009, 46, 3108-3116.	2.2	31
112	Restoration of Vitamin C Synthesis in Transgenic Guloâ^'/â^' Mice by Helper-Dependent Adenovirus-Based Expression of Gulonolactone Oxidase. Human Gene Therapy, 2008, 19, 1349-1358.	2.7	8
113	Cigarette Smoke Suppresses Type I Interferon-Mediated Antiviral Immunity in Lung Fibroblast and Epithelial Cells. Journal of Interferon and Cytokine Research, 2008, 28, 167-179.	1.2	53
114	Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand. Journal of Immunology, 2008, 181, 6702-6706.	0.8	113
115	FimH Adhesin of Type 1 Fimbriae Is a Potent Inducer of Innate Antimicrobial Responses Which Requires TLR4 and Type 1 Interferon Signalling. PLoS Pathogens, 2008, 4, e1000233.	4.7	108
116	Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. Journal of Leukocyte Biology, 2008, 83, 774-784.	3.3	99
117	Antigen Presentation by Exosomes Released from Peptide-Pulsed Dendritic Cells Is not Suppressed by the Presence of Active CTL. Journal of Immunology, 2007, 179, 5024-5032.	0.8	117
118	Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7506-7511.	7.1	137
119	Identification of a Novel Pathway Essential for the Immediate-Early, Interferon-Independent Antiviral Response to Enveloped Virions. Journal of Virology, 2006, 80, 226-235.	3.4	61
120	Induction of Innate Immunity against Herpes Simplex Virus Type 2 Infection via Local Delivery of Toll-Like Receptor Ligands Correlates with Beta Interferon Production. Journal of Virology, 2006, 80, 9943-9950.	3.4	90
121	ICPO Prevents RNase L-Independent rRNA Cleavage in Herpes Simplex Virus Type 1-Infected Cells. Journal of Virology, 2006, 80, 218-225.	3.4	25
122	The IFN-Independent Response to Virus Particle Entry Provides a First Line of Antiviral Defense That Is Independent of TLRs and Retinoic Acid-Inducible Gene I. Journal of Immunology, 2006, 177, 8008-8016.	0.8	92
123	Analysis of Anti-Interferon Properties of the Herpes Simplex Virus Type I ICPO Protein. , 2005, 116, 195-205.		15
124	The role of ICPO-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Molecular Therapy, 2005, 12, 1101-1110.	8.2	53
125	Herpesviruses and the Innate Immune Response. Viral Immunology, 2005, 18, 267-281.	1.3	94
126	Functional inaccessibility of quiescent herpes simplex virus genomes. Virology Journal, 2005, 2, 85.	3.4	27

#	Article	IF	CITATIONS
127	The Herpes Simplex Virus ICPO RING Finger Domain Inhibits IRF3- and IRF7-Mediated Activation of Interferon-Stimulated Genes. Journal of Virology, 2004, 78, 1675-1684.	3.4	237
128	Innate Cellular Response to Virus Particle Entry Requires IRF3 but Not Virus Replication. Journal of Virology, 2004, 78, 1706-1717.	3.4	181
129	Activation and Inhibition of Virus and Interferon: The Herpesvirus Story. Viral Immunology, 2002, 15, 3-15.	1.3	22
130	Herpes Simplex Virus ICPO and ICP34.5 Counteract Distinct Interferon-Induced Barriers to Virus Replication. Journal of Virology, 2002, 76, 1995-1998.	3.4	102
131	Herpes Simplex Virus Triggers and Then Disarms a Host Antiviral Response. Journal of Virology, 2001, 75, 750-758.	3.4	241
132	Evidence that Herpes Simplex Virus VP16 Is Required for Viral Egress Downstream of the Initial Envelopment Event. Journal of Virology, 2000, 74, 6287-6299.	3.4	119
133	Herpes Simplex Virus ICP0 Mutants Are Hypersensitive to Interferon. Journal of Virology, 2000, 74, 2052-2056.	3.4	191
134	Truncation of the C-Terminal Acidic Transcriptional Activation Domain of Herpes Simplex Virus VP16 Renders Expression of the Immediate-Early Genes Almost Entirely Dependent on ICPO. Journal of Virology, 1999, 73, 9726-9733.	3.4	48
135	The Myxoma Virus M-T4 Gene Encodes a Novel RDEL-Containing Protein That Is Retained within the Endoplasmic Reticulum and Is Important for the Productive Infection of Lymphocytes. Virology, 1997, 239, 360-377.	2.4	83
136	Myxoma Virus M-T7, a Secreted Homolog of the Interferon-Î ³ Receptor, Is a Critical Virulence Factor for the Development of Myxomatosis in European Rabbits. Virology, 1996, 215, 17-30.	2.4	138
137	Systematic Genome-Scale Identification of Host Factors for SARS-CoV-2 Infection Across Models Yields a Core Single Gene Dependency; <i>Ace2</i> . SSRN Electronic Journal, 0, , .	0.4	0